TMS Co (TSE:4891) Selling, General, & Admin. Expense: 円173.27 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4891 TMS Co Ltd TSE:4891
32 GF Score
Price 円101.00
! 1 Warning Sign
View Full Analysis

What is TMS Co Selling, General, & Admin. Expense?

TMS Co TSE:4891 +1.00% 32 Selling, General, & Admin. Expense is 円173.27 Mil as of Dec. 2025. GuruFocus rates TSE:4891 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. TMS Co's selling, general, & admin. expense for the three months ended in Dec. 2025 was 円0.00 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was 円173.27 Mil.


TMS Co  (TSE:4891) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


TMS Co Selling, General, & Admin. Expense Related Terms


TMS Co Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for TMS Co's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMS Co Selling, General, & Admin. Expense Chart

TMS Co Annual Data
Trend Feb21 Feb22 Feb23 Feb24 Feb25
Selling, General, & Admin. Expense
117.92 506.61 222.25 335.53 286.69

TMS Co Quarterly Data
Feb21 Feb22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Feb25 May25 Aug25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.65 0.00 102.17 71.09 0.00

TSE:4891 vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, TMS Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TMS Co Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TMS Co's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where TMS Co's Selling, General, & Admin. Expense falls into.


TSE:4891
32GF Score
TMS Co Ltd TSE:4891
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMS Co Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円173.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of 円173.27 Mil mean?
TMS Co (TSE:4891) has a Selling, General, & Admin. Expense of 円173.27 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on TMS Co and its competitors.
Is TMS Co's Selling, General, & Admin. Expense too high?
TMS Co's current Selling, General, & Admin. Expense is 円173.27 Mil. Overall, TMS Co has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's Selling, General, & Admin. Expense compare to VRTX and REGN?
TMS Co's Selling, General, & Admin. Expense of 円173.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on TMS Co and its competitors. TMS Co's current Selling, General, & Admin. Expense is 円173.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current Selling, General, & Admin. Expense of 円173.27 Mil. The current Selling, General, & Admin. Expense is 円173.27 Mil. TMS Co's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For TMS Co (TSE:4891), the current Selling, General, & Admin. Expense is 円173.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TMS Co Business Description

Address 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo, JPN, 183-0055
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
32GF Score

Get the complete analysis for TSE:4891

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円101.00
Price